What’s CANNABIS SCIENCE INC (OTCMKTS:CBIS) Upside After This Short Interest Decrease?

April 20, 2018 - By Stephen Andrade

Cannabis Science, Inc. (OTCMKTS:CBIS) Logo

Investors sentiment decreased to 1.33 in 2017 Q4. Its down 6.67, from 8 in 2017Q3. It turned negative, as 3 investors sold Cannabis Science, Inc. shares while 0 reduced holdings. 3 funds opened positions while 1 raised stakes. 277,539 shares or 8.94% less from 304,780 shares in 2017Q3 were reported.
Rothschild Investment Corporation Il reported 0% in Cannabis Science, Inc. (OTCMKTS:CBIS). Moreover, Churchill Mgmt Corporation has 0% invested in Cannabis Science, Inc. (OTCMKTS:CBIS) for 13,389 shares. Frontier Invest Mngmt holds 0% in Cannabis Science, Inc. (OTCMKTS:CBIS) or 20,000 shares. Silvercrest Asset Grp Inc Ltd Com has 10,000 shares for 0% of their portfolio. Massmutual Trust Company Fsb Adv owns 0% invested in Cannabis Science, Inc. (OTCMKTS:CBIS) for 150 shares. 40,000 were accumulated by North Star Asset Management Inc. Neville Rodie & Shaw reported 170,000 shares or 0% of all its holdings. Stonebridge Cap Lc has invested 0% of its portfolio in Cannabis Science, Inc. (OTCMKTS:CBIS).

The stock of CANNABIS SCIENCE INC (OTCMKTS:CBIS) registered a decrease of 5.95% in short interest. CBIS’s total short interest was 210,200 shares in April as published by FINRA. Its down 5.95% from 223,500 shares, reported previously. The short interest to CANNABIS SCIENCE INC’s float is 0.01%.

The stock decreased 2.27% or $0.001 during the last trading session, reaching $0.056. About shares traded. Cannabis Science, Inc. (OTCMKTS:CBIS) has 0.00% since April 20, 2017 and is . It has underperformed by 11.55% the S&P500.

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid pharmaceutical products primarily in the United States. The company has market cap of $142.90 million. The firm is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. It currently has negative earnings. The Company’s drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis therapy for neurological conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.